Document Detail


Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent.
MedLine Citation:
PMID:  20358534     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previously the polymer-free sirolimus-eluting YUKON-Choice stent (A) has demonstrated noninferiority compared to the polymer-based paclitaxel-eluting TAXUS stent (B). To test for long-term equivalency in unselected real-world coronary lesions of various complexities, we retrospectively compared both stents. METHODS: A total of 410 patients with symptomatic coronary artery disease (CAD) were treated with stent A (n = 205) or stent B (n = 205). Baseline clinical characteristics, lesion location, and length and the number of stents implanted per lesion were equally distributed. Clinical follow-up with assessment of major adverse cardiac events (MACE) and noncardiac deaths was obtained at 9 and 12 months. RESULTS: Nominal stent diameter and nominal length of the stented segment were without differences between the groups. The incidence of MACE after 12 months was significantly higher in group A (35.1%) compared to group B (16.6%, P = .001). This was mainly due to increased rates of target-lesion revascularizations in group A (13.7%) vs group B (4.4%, P = .005). No significant differences in target-vessel revascularizations and non-target-vessel revascularizations were observed. In group B, 1 stent thrombosis was documented (0.5%) vs none in group A (P > .05); in each group 1 myocardial infarction (MI), but no cardiac deaths occurred; 3 noncardiac deaths in group A (1.5%) vs 7 in group B (3.4%) were observed (P = .3). CONCLUSIONS: In contrast to our previous findings indicating no differences in MACE between patients treated with the polymer-free sirolimus-eluting YUKON-Choice stent and the polymer-based paclitaxel-eluting TAXUS stent at 6 months, we herewith show that 12 months after percutaneous coronary intervention (PCI) of real-world coronary lesions the YUKON stent appears to be inferior due to increased target-lesion revascularization (TLR) rates as a consequence of delayed restenosis.
Authors:
Johannes Ruef; Hans St?rger; Franz Schwarz; J?rgen Haase
Related Documents :
23302004 - Orthotopic bladder replacement in women: focus on functional results of a retrospective...
23220244 - Half-century follow-up after ureterosigmoidostomy in early childhood.
3162044 - Clinical experience of percutaneous transluminal coronary angioplasty--technique and re...
14699214 - Immediate and medium-term outcomes following the treatment of very long (> or =50 mm) c...
15493034 - Fungicidal effect of diode laser irradiation in patients with denture stomatitis.
23105124 - Comparison of a powered bone marrow biopsy device with a manual system: results of a pr...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Clinical cardiology     Volume:  33     ISSN:  1932-8737     ISO Abbreviation:  Clin Cardiol     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-05-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E33-8     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Wiley Periodicals, Inc.
Affiliation:
Red Cross Hospital Cardiology Center, Frankfurt, Germany. j.ruef@kardiocentrum.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coronary Angiography
Coronary Disease / drug therapy*
Coronary Restenosis / epidemiology*,  radiography
Drug-Eluting Stents*
Female
Graft Occlusion, Vascular / epidemiology,  radiography
Humans
Immunosuppressive Agents / administration & dosage*
Male
Paclitaxel / administration & dosage*
Prosthesis Design
Retrospective Studies
Sirolimus / administration & dosage*
Treatment Outcome
Tubulin Modulators / administration & dosage*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Tubulin Modulators; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Technetium-99m-sestamibi Redistribution after Exercise Stress Test Identified by a Novel Cardiac Gam...
Next Document:  Evaluation of the Surface ECG in Detecting Isthmus Conduction Block after Ablation of Typical Atrial...